Technical analysis of Boundless Bio, Inc. (BOLD): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.
Price Performance
| 1 month | -1.92% |
| 3 months | +96.15% |
| Year-to-date | +133.75% |
| 1 year | +146.05% |
52-Week Range
| 52-week High | $3.16 |
| 52-week Low | $0.96 |
| Avg Volume (90d) | 928K |
Technical Indicators
| SMA 50 | $2.71 |
| SMA 200 | $1.70 |
| Beta | -0.26 |
| 30-day Volatility (annualised) | 23.4% |
| Price vs SMA 50 | +3.5% |
| Price vs SMA 200 | +65.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.40 | |
| 2025-11 | $1.17 | -16.4% |
| 2025-12 | $1.20 | +2.6% |
| 2026-01 | $1.16 | -3.3% |
| 2026-02 | $1.16 | +0.0% |
| 2026-03 | $1.10 | -5.2% |
| 2026-04 | $1.46 | +32.7% |
| 2026-05 | $1.45 | -0.7% |
| 2026-06 | $2.50 | +72.4% |
| 2026-07 | $2.50 | +0.0% |
| 2026-08 | $2.81 | +12.4% |
| 2026-09 | $2.81 | -0.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.06 | $3M |
| 2026-09-14 | | |
| 2026-09-14 | $-0.03 | $278M |
| 2026-09-14 | | $898M |
Price
| Price | $2.82 |
| Market Cap | $63M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.96 |
| EV / EBITDA | -0.76 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 9.48 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -2.63 |